Table 1.
Association of common genomic alteration with overall survival and time on treatment with first-line ARSI
| Gene/pathway alteration | Univariate P value for survival from first-line ARSI (CPE, n = 128 or as indicated) | Univariate P value for time on treatment with first-line ARSI (CPE, n = 108 or as indicated) |
| RB1 | 0.002 (CPE 0.768) | <0.001 (CPE 0.818) |
| TP53 | 0.072 (CPE 0.605) | 0.046 (CPE 0.609) |
| WNT pathway | 0.115 | 0.153 |
| ETS fusion | 0.159 | 0.206 |
| APC | 0.255 | 0.167 |
| CTNNB1 | 0.274 | 0.448 |
| ATM | 0.331 | 0.850 |
| BRCA2 | 0.327 | 0.418 |
| BRCA2/BRCA1/ATM | 0.495 | 0.611 |
| AKT1 | 0.558 | 0.053 |
| RNF43 | 0.614 | 0.844 |
| AR | 0.658 | 0.005 (CPE 0.651) |
| PTEN | 0.676 | 0.412 |
| PI3K pathway | 0.699 | 0.138 |
| PIK3CA | 0.716 | 0.165 |
| PIK3R1 | 0.752 | 0.892 |
| PIK3CB | 0.799 | 0.277 |
| BRCA1 | 0.809 | 0.998 |
| NEPC score | 0.218 (n = 99) | 0.930 (n = 80) |
| AR signaling score | 0.847 (n = 99) | 0.847 (n = 80) |
| RB1 loss score | <0.001 (n = 99) | 0.014 (n = 80) |
| CCP score | 0.002 (n = 99) | 0.045 (n = 80) |
| AR-V7 SRPM | 0.524 (n = 75) | 0.329 (n = 56) |
| AR-V7/ARpromoter1-2 | 0.475 (n = 75) | 0.378 (n = 56) |
| AR-V3 SRPM | 0.444 (n = 75) | 0.077 (n = 56) |
Univariate log-rank analysis for association of common genomic alterations with survival from the start of a first-line ARSI for mCRPC (n = 128), and with time on treatment with a first-line ARSI for mCRPC (n = 108 patients who received a first-line ARSI as monotherapy). Where indicated, analysis was limited to a subset of patients who had RNA-sequencing data either from polyA libraries or both polyA and capture libraries. P < 0.05 are highlighted in bold.